Research progress of different chemotherapy regimens combined with radiotherapy for nonsmall cell lung cancer

doi:10.3760/cma.j.issn.1673422X.2015.05.017

Abstract

SHI Sha-Peng, HAN Bo. Research progress of different chemotherapy regimens combined with radiotherapy for nonsmall cell lung cancer[J]. Journal of International Oncology, 2015, 42(5): 381-384.

［1］秦楚，王朝霞 . 非小细胞肺癌个体化治疗研究进展［J］. 中华临床医师杂志, 2013, 7(11): 96819686. ［2］ Curran WJ, JR, Paulus R, et al. Sequential vs. concurrent chemoradiation for stage Ⅲ nonsmall cell lung cancer:randomized phase Ⅲ trial RTOG9410［J］. J Nati Cancer Inst, 2011, 103(19):14521460. ［3］ Lin Q, Liu YE, Ren XC, et al. Dose escalation of accelerated hypofractionated threedimensional conformal radiotherapy (at 3Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in unresectable stage Ⅲ nonsmallcell lung cancer:a phase Ⅰ trial［J］. Radiation Oncology, 2013, 8(1): 201. ［4］ Mauguen A, Le Péchoux C, Saunders MI, et al. Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data metaanalysis［J］. J Clin Oncol, 2012, 30(22): 27882797 ［5］ Cox JD. Are the results of RTOG0617 mysterious?［J］. Int J Radiat Oncol Biol Phys, 2012, 82(3): 10421044. ［6］ Tucker S. The role of pemetrexed in second line chemoradiotherapy for advanced nonsmall cell lung cancer［J］. Curren Drug Targets, 2010,11(1): 5860. ［7］吴灿，许晓峰，肖宏卫，等. 培美曲塞加奈达铂联合三维适形放疗同步序贯治疗局部晚期非小细胞肺癌的疗效观察［J］. 中国医药指南， 2012, 10(4): 79. ［8］ Esteban E, CasillasM, Cassinello A. Pemetrexed in firstline treatment of nonsmall cell lung cancer ［J］. Cancer Treat Rev, 2009, 35(4): 364373. ［9］莫玉珍, 宁四海, 李高峰，等. 适形调强放疗联合培美曲塞及顺铂同步和巩固化疗治疗Ⅲ期肺腺癌临床研究［J］. 实用肿瘤杂志, 2011, 25(3):237240. ［10］胡建新. 非鳞癌局部晚期肺癌三维适形放疗联合培美曲塞的疗效［J］. 实用医学杂志， 2012, 28（12）： 20142016. ［11］蔡勇, 王季颖 . 适形放疗联合培美曲塞同步治疗局部晚期老年非鳞形肺癌的临床研究［J］. 中国肿瘤临床， 2011, 38（12）：12271229. ［12］ Mornex F, Peignaux K. Phase Ⅰ study of pemetrexed and cisplatin with concurrent highdose thoracic radiation after induction chemotherapy in patients with unresectable locally advanced nonsmall cell lung cancer［J］. Lung Cancer, 2013, 2(85): 7579. ［13］潘汉成，陆超，黄龙璋. 诱导化疗联合同步放化疗对局部晚期非小细胞肺癌的疗效分析［J］. 肿瘤药学, 2012, 2（6）: 449451. ［14］ Galetta D, Rossi A . The impact of personalized medicine on survival:comparisons of results in metastatic breast,colorectal and non small cell lung cancer［J］. Cancer Treat Review, 2014, 40(4): 485494. ［15］ Crvenkova S, Ivkovski Lj, Dimovski A, et al. Effectiveness of erlotinib as a second line therapy for patients with epidermal growth factor receptor mutation in non small cell lung cancer:our clinical experience［J］.Prilozi, 2012, 33(1): 30311. ［16］ Janne PA, Wang X, Socinski MA, et al. Randomized phase Ⅱ trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma:CALGB30406 trial.［J］. Clin Oncol, 2012,30(17): 20632069. ［17］接亚敏, 韩北秋, 乔文波, 等. 放射性肺损伤相关临床因素的研究［J］. 中华肿瘤防治杂志, 2011, 18(8): 12011203. ［18］ Hirsh V, Melosky B. Management of common toxicities in metastatic NSCLC related to antilung cancer therapies with EGFRTKIS［J］. Front Oncol, 2014, 4： 238. ［19］ Patel SH, Ma Y, Wernicke AG, et al. Evidence supporting contemporary postoperative radiation therapy(PORT) using linear accelerators in N2 lung cancer［J］. Lung Cancer, 2014, 84(2)： 156160. ［20］ Driesen P, Lambrechts M. A phase II singlearm study of induction chemotherapy with cisplatin and gemcitabine followed by concurrent cisplatin and gemcitabine with thoracic radiation for unresectable locally advanced nonsmall cell lung cancer［J］. Adv Med Oncol, 2013， 5(3)： 159168. ［21］ Jane AK, Choy H, Mouqhan J, et al. RTOG0017： a phase Ⅰtrial of concurrent gemcitabine/carboplatin or gemcitabine/paclitaxel and radiation therapy followed by adjuvant chemotherapy for patients with favorable prognosis inoperable stage ⅢA/B non small cell lung cancer［J］. J Thorac Oncol, 2012, 4(1)： 8086. ［22］ Oh IJ, Kim KS, Kim YC, et al. A phase III concurrent chemoradiotherapy trial with cisplatin and paclitaxel or docetaxel or gemcitabine in unresectable nonsmall cell lung cancer： KASLC 0401［J］. Cancer Chemother Pharmacol, 2013, 72(6)： 12471254. ［23］ Maráz A, Furák J. Acute oesophageal toxicity related to paclitaxelbased concurrent chemoradiotherapy for nonsmall cell lung cancer［J］. Anticancer Res, 2013, 33 (4)： 17371741. ［24］ Lu B, Sun L, Yan X, et al. Intratumoral chemotherapy with paclitaxel lipsome combined with systemic chemotherapy： a new method of neoadjuvant chemotherapy fot stage Ⅲ unresectable nonsmall cell lung cancer［J］. Med Oncol, 2015, 32(1)： 345. ［25］ Diqumarti R, Bapsy PP, Suresh AV, et al. Bavituximab plus paclitaxel and carboplatin for the treatment of advanced non small cell lung cancer［J］. Lung Cancer, 2014, 86(2)： 231236. ［26］石安辉，朱广迎. 局部晚期非小细胞肺癌同步放化疗中紫杉醇两种用法的多中心、随机对照研究［J］. 中国肺癌杂志， 2011, 14(3)： 227232.

Research progress of different chemotherapy regimens combined with radiotherapy for nonsmall cell lung cancer

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 0

Recommended Articles

Metrics

Comments